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Apoptosis is a conserved cellular pathway that
results in the activation of cysteine-aspartyl prote-
ases, or caspases. To dissect the nonredundant
roles of the executioner caspase-3, -6, and -7 in
orchestrating apoptosis, we have developed an
orthogonal protease to selectively activate each
isoform in human cells. Our approach uses a split-
tobacco etch virus (TEV) protease under small-mole-
cule control, which we call the SNIPer, with caspase
alleles containing genetically encoded TEV cleavage
sites. These studies reveal that all three caspases are
transiently activated but only activation of caspase-3
or -7 is sufficient to induce apoptosis. Proteomic
analysis shown here and from others reveals that
20 of the 33 subunits of the 26S proteasome can be
cut by caspases, and we demonstrate synergy
between proteasome inhibition and dose-dependent
caspase activation. We propose a model of proteo-
lytic reciprocal negative regulation with mechanistic
implications for the combined clinical use of protea-
some inhibitors and proapoptotic drugs.
INTRODUCTION
Apoptosis, or programmed cell death, is a ubiquitous and
conserved cellular pathway required for development, immune
cell maturation, and to prevent oncogenesis (Taylor et al.,
2008). Apoptosis is triggered by signaling events involving
a diverse array of protein networks, organelles, and macromo-
lecular complexes that converge upon the activation of cas-
pases (Fuentes-Prior and Salvesen, 2004). The executioner
caspases are the final proteases to be activated in apoptosis.
This leads to cleavage of upwards of 1000 proteins (Dix et al.,
2008; Mahrus et al., 2008) to produce the characteristic
apoptotic phenotypes of membrane blebbing, nuclear conden-
sation, DNA fragmentation, and ultimately phagocytosis by
immune cells. Executioner caspases have been recently linkedto nonapoptotic phenotypes such as axonal pruning, stem cell
differentiation, and red blood cell enucleation (Yi and Yuan,
2009). The cellular processes that stop caspases short of
inducing apoptosis in these diverse biological settings remain
a mystery.
There are 12 caspase isoforms in humans, but their precise
and nonredundant roles for mediating apoptosis, nonapoptotic
phenotypes, and innate immunity are only beginning to be fully
elucidated. Extensive biochemical and structural analyses indi-
cate that the inflammatory and initiator caspases are recruited
to larger complexes that induce caspase dimerization, autopro-
teolysis, and protease activation (Shi, 2004). Upon activation, the
apoptotic initiator caspase-8 and -9 cleave the executioner
procaspase-3, -6, and -7. The executioner caspases are trans-
lated as inactive dimers; there are at least two sites of processing
in the executioner caspases; and the specific role of each
proteolytic event in regulating executioner caspase activity is still
unclear, both in vitro and in cells, as is the role of the prodomain
in executioner caspase function.
Gene knockout studies in murine embryonic fibroblasts
demonstrate that cells deficient in both caspase-3 and -7 are
more resistant to a variety of apoptotic stimuli as compared to
single knockouts, suggesting functional redundancy in these
two executioner isoforms (Lakhani et al., 2006). Furthermore,
single-cell studies reveal that the induction of executioner
caspase activity is highly stochastic (Albeck et al., 2008b;
Rehm et al., 2002). To further probe the function of each caspase
with sharp temporal resolution, we needed to activate an indi-
vidual isoform selectively and synchronously. Recent progress
was reported toward building small-molecule activators of the
procaspases (Wolan et al., 2009), but these compounds are
not yet selective enough to trigger each one of the caspases indi-
vidually.
To address the goal of activating a single executioner caspase
isoform in a site-selective manner, we describe the optimization
of a previously split NIa tobacco etch virus (TEV) protease (Wehr
et al., 2006). We demonstrate that an engineered variant of split-
TEV can be robustly activated in cells to specifically cleave each
of the executioner caspase isoforms. These studies reveal that
activation of caspase-3 or -7, but not caspase-6, is sufficient
to induce apoptosis. Remarkably, the activation is transient forCell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc. 637
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Figure 1. Engineering the SNIPer for Condi-
tional Proteolysis
(A) Generalized scheme for a ligand-inducible
orthogonal protease based on the protein comple-
mentation system.
(B) Plasmids with deletions at the C terminus of
Frb-C-TEV or empty vector (EV) were cotrans-
fected with FKBP-N-TEV and ECFP-TevS-YPET
in 293T cells. Ten nanomolar Rap was added for
12 hr and FRET measurements were recorded
using a fluorescent microplate reader. Data are
presented as corrected averages of FRET/ECFP
from an experiment performed in quadruplicate
(error bars ± standard deviation [SD]).
(C) N-TEV and C-TEV-219 were fused to either
FKBP or Frb and assayed by FRET in quadrupli-
cate as above. Transfections were performed
with 33 or 123 molar excess of Tev constructs
to reporter plasmid (error bars ± SD).
(D) The kinetics and cell-to-cell heterogeneity of
SNIPer-mediated protease activity were com-
pared to endogenous caspase activation by live-
cell fluorescent imaging. HEK293 cells were
transfected with the SNIPer and ECFP-TevS-
YPET or ECFP-DEVDR-YPET, a reporter for
caspase-3/-7 activity in cells, and treated with
10 nM Rap or 1 mM staurosporine. Live-cell FRET
measurements were recorded every 15 min.
See also Figure S1.each isoform. These data support a model of antagonistic prote-
olysis between the executioner caspases and the proteasome.
RESULTS
The SNIPer: Design, Optimization, and Characterization
in Mammalian Cells
Our initial split-TEV construct was based on a previous design
developed for protein-complementation assays (Wehr et al.,
2006) (Figure 1A). The full-length TEV variant S219V was split
into two component fragments: N-TEV (residues 1–118) and
C-TEV (residues 119–242). This design inactivates TEV protease
by separating the catalytic triad residues Asp44 and His81 from
the Cys151 nucleophile. N-TEV was fused to the C terminus of
FKBP with a 10 amino acid (GGGGS)2x linker between the two
domains, and C-TEV was fused to the C terminus of Frb (the
rapamycin-binding domain of mTOR kinase). Therefore,
protease activity is conditionally restored by the addition of
rapamycin, which promotes split-TEV fragment association
and ligand-dependent protein folding.
We assayed for reconstituted protease activity in 293T cells by
cotransfecting both N- and C-TEV halves and a FRET-based
ECFP-YPET reporter that is cleaved by TEV. In the presence of
rapamycin (Rap), the split-TEV construct extending to residue
242 cleaved the protease reporter as compared to an empty
vector control (Figure 1B). However, significant processing
also occurred in the absence of Rap, suggesting that the two
halves can associate and reconstitute activity in the absence
of a small-molecule dimerizer. Another group recently imple-
mented the published N-TEV and C-TEV design in mammalian
cells and similarly observed leaky TEV protease activity in the638 Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc.absence of Rap (Williams et al., 2009). They reduced Rap-inde-
pendent activation by lowering the amount of split-TEV DNA that
was transiently transfected or by targeting one fragment to the
cell membrane via a genetically encoded myristoylation tag.
However, our goal was to engineer cell death pathways using
stable cell lines, which requires a split-TEV design with no back-
ground activity. We hypothesized that the C terminus of the TEV
was causing spontaneous refolding of the fragments in the
absence of Rap (Figure S1A, available online, for a model).
A systematic set of deletion mutants was created from the
C-TEV119–242 fragment to generate four truncated C-TEV
constructs. Coexpression of FKBP-N-TEV and Frb-C-TEV-219
yielded inducible proteolysis upon addition of Rap with reduced
leaky proteolytic activity in mock-treated cells as confirmed by
theFRETassay (Figure 1B) and immunoblot analysis (Figure S1B,
top panel).
Further optimization was required due to detectable TEV
activity for FKBP-N-TEV and Frb-C-TEV-219 in the absence of
Rap (Figure 1C and Figure S2B, bottom panel). We tested the
opposite FKBP and Frb protein fusions to N-TEV and to the
enhanced C-TEV-219 fragment, and we observed that Frb-N-
TEV(1–118) and FKBP-C-TEV(119–219) maintained robust TEV
activity in the presence of Rap with little background. As an initial
test of split-TEV stability, we found that proteolysis of the FRET
reporter was not enhanced after treatment with Rap and 500 nM
PS-341 (Bortezomib), a clinically available proteasome inhibitor
(Figure S1C), indicating that a proteasome inhibition was not
sufficient to promote increased split-TEV activity in cells. Each
split-TEV protein fragment was also detected by immunoblotting
after blocking protein translation with cyclohexamide for 8 hr,
suggesting both were stable in cells (Figure S1D). Both removal
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Figure 2. Design and In Vitro Characteriza-
tion of Orthogonal Procaspase-3 and -7
Alleles
(A) We employed the indicated TevS insertion
strategy to convert caspase sites into SNIPer
cleavage sites as shown for caspase-3. The
sequences (P4-P10 with a red bar to denote the
scissile bond) and location of site 1 and site 2 are
shown in the context of executioner caspase
domain structure below.
(B) In vitro activation of WT procaspase-3 (Casp3-
WT) or Casp3-TevS was assayed by expressing
each allele in E. coli, treating with either rat Gran-
zyme-B (20 nM), or TEV Protease (1.1 mM) for
1 hr, and measuring caspase activity with 10 mM
Ac-DEVD-AFC. Data are presented as the average
rate of substrate cleavage (relative fluorescence
units [RFUs] s1) from an experiment performed
in triplicate (error bars ± SD).
(C) Caspase activity of the procaspase-3 and -7
matrix of orthogonal alleles was performed as
above and is presented as a heat map. Abbrevia-
tions: WT, wild-type; TevS-1, TevS insertion at
site 1; TevS-2, TevS insertion at site 2; D2A-
TevS-2, TevS insertion at site 2with a noncleavable
site 1; and TevS-(1,2), TevS insertions at site 1 and
site 2.
See also Figure S2.of the C-terminal end of the C-TEV fragment and fusion pair
optimization to FKBPandFrbwere necessary to generate a rapa-
mycin-inducible split-TEV protease for mammalian cells. We
refer to this optimized construct pair as the SNIPer (single nick
in proteome) because there are no known natural TEV cleavage
sites in the human proteome except for those we introduce.
We observed rapid activation of the SNIPer in individual cells
(Figure 1D, left panel) using the TevS-FRET reporter in transiently
transfected HEK293 cells. Cells weremonitored over a 3 hr time-
frame over which a linear increase in TEV activity was measured
by single-cell fluorescent microscopy. Approximately 50%of the
ECFP-YPETENLYFQjS substrate was cleaved by 100 ± 20 min.
Importantly, activation of the SNIPer at the single-cell level was
more synchronous than endogenous caspase pathways during
experiments in which SNIPer-expressing cells were directly
compared to HEK293 cells transfected with ECFP-YPETDEVDjR,
a reporter for caspase-3 and -7 activity (Albeck et al., 2008a)
(Figure 1D, right panel), and treated with 1 mM staurosporine
(STS). We conclude that SNIPer activation kinetics matches or
exceeds endogenous DEVDase activation kinetics during
apoptosis, which prompted its further use to probe executioner
caspase signaling in cells.
Engineering Orthogonal Procaspase-3 and -7 Alleles for
Selective Activation by the SNIPer
The executioner caspases are translated as inactive zymogens
that are cleaved by initiator caspases, by other executioner cas-
pases in trans, or by autoactivation. Two sites of processing exist
in procaspase-3 and -7: one at the junction of the prodomain and
large subunit (site 1) and the second between the large and small
subunits in the intersubunit linker (site 2) (Earnshaw et al., 1999).To date, there are no reported crystal structures of procaspase-3
or procaspase-7 with defined electron density in the intersubunit
linker or the prodomain. However, previous studies have shown
that mutation of several residues within the ‘‘loop bundle’’ of the
intersubunit linker of caspase-3 influences the activity of the
protease (Feeney et al., 2006). Therefore, we inserted a TEV
recognition sequence (TevS) into the P1 position at site 2 on pro-
caspase-3, replacing the P1 Asp of the endogenous caspase
site, P5-IETD-P10, with the preferred P6 Glu for the Tev cleavage
site (TevS), P7-ENLFYQ-P10. This resulted in a chimeric
substrate at site 2 (IETENLYFQ) that maintained the integrity of
the caspase cleavage site from P4–P2 while eliminating the
aspartic acid critical for cutting by the caspases themselves
(Figure 2A, top panel). In principle, this approach would render
the sites cleavable by the SNIPer only. As caspases and TEV
protease share similar preference for the small P10 residues
(Gly, Ser, and Ala), the wild-type (WT) peptide sequence after
the scissile bondwas alsomaintained. Once the TevS is cleaved,
a small peptide ‘‘scar’’ is left behind with an ENLYFQ sequence
on the C terminus.
With this insertion strategy we generated four alleles in both
procaspase-3 and -7: one where TevS was inserted between
the prodomain and the large subunit (TevS-1), one where the
TevS was inserted between the large and small domains
(TevS-2), one where two insertions were made (TevS-1,2), and
one that contained the TevS inserted between the large and
small subunits but that also contained a mutation of Asp to Ala
mutation at site 1 to prevent prodomain cleavage (D2A-TevS-2)
(Figure 2A, bottom panel). To begin to test the impact of these
mutations on processing and activity, a His-tagged version of the
Casp3-D2A-TevS-2 protein was overexpressed in E. coli andCell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc. 639
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Figure 3. Phenotypic Analysis of SNIPer-
Mediated Activation of Procaspase-3 and
-7 in Cells
(A) HEK293 cells stably expressing the SNIPer and
indicated procaspase-3/-7 alleles were treated
with DMSO or 10 nM Rap over the course of 16 hr.
The indicated cells lines were assayed for cas-
pase activity using the Caspase-Glo-3/-7 assay
at 6 hr (top row), for total cellular viability using
the Cell-Titer-Glo assay at the indicated times
(line graph, bottom row), and for phosphatidylser-
ine (PS) exposure/membrane integrity by staining
with GFP-Annexin-V and propidium iodide (PI)
and imaging by fluorescent microscopy at 8 hr.
Each data point is presented as an average of trip-
licate experiments (error bars ± SD).
(B) HEK293 stably expressing procaspase-3/-7
D2A-TevS and TevS-(1,2) alleles were analyzed
for caspase activity and for GFP-Annexin-V/PI
staining exactly as above.
See also Figure S3.purified by Ni-NTA affinity chromatography. Casp3-D2A-TevS-2
was coincubated with recombinant TEV protease, and the pro-
cessed samples were analyzed by SDS-PAGE to confirm that
the engineered caspase construct was indeed cleaved at the
expected single site (Figure S2A). Furthermore, the measured
catalytic efficiency (kcat/KM) for the engineered caspase was in
good agreement with the value for WT active caspase-3
produced in our lab (Figure S2B).
To further probe the functional consequence of processing at
site 1 and site 2 in vitro, we constructed amatrix of the three pro-
caspase-3 and -7 alleles harboring TevS sites that replace one or
both endogenous caspase processing sites. Granzyme-B (GrB),
a serine protease secreted by cytotoxic T lymphocytes, is
capable of cleaving procaspase-3 at site 2 (Casciola-Rosen
et al., 2007), but it does not process Casp3-TevS-2 as that
cleavage site is mutated. Incubation of Casp3-WT and Casp3-
TevS alleles with active GrB or Tev confirmed that Casp3-
TevS-2 is an orthogonal caspase; it is activated by TEV protease
but not by GrB (Figure 2B).
Each procaspase-3 and -7 allele was expressed as a proen-
zyme in E. coli and treated with GrB or TevS for 1 hr, and relative
caspase activity was measured with Ac-DEVD-AFC (Figure 2C).
Immunoblots confirmed the predicted cleavage patterns for TEV
protease or GrB for procaspase-3 allele series (Figure S2C).
Cleavage by GrB at IETD175 at site 2 was sufficient to activate
WT and TevS-1 procaspases variants, both of which are WT
for site 2. TEV processing at TevS-2 was sufficient to activate
both caspase-3 and -7-TevS-2, regardless of whether the pro-
domain was cleavable. TEV protease processing at TevS-1
was not sufficient to induce activity for either isoform. Together,
these results confirm that processing at site 2 is both necessary
and sufficient for activation in vitro by either TEV protease or GrB.
Processing of the prodomain is neither sufficient for activation640 Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc.nor necessary for full levels of activation in conjunction with pro-
cessing at the intersubunit linker.
Selective Activation of Orthogonal Procaspase-3
and -7 Alleles in Stable Human Cell Lines
The matrix of caspase-TevS alleles was stably engineered as
single-copy integrants into HEK293 cells as described in the
Extended Experimental Procedures in order to minimize the
overexpression phenotypes associated with transient transfec-
tion. HEK293 SNIPer cell lines expressing Casp3-WT, Casp3-
TevS-1, or Casp3-TevS-2 were induced for 6 hr with 10 nM
Rap and assayed for DEVDase activity. Addition of Rap induced
an 8-fold increase in caspase-3 activity in the Casp3-TevS-2 line
as compared to the same cells treated with DMSO only
(Figure 3A, left top and bottom panels). After 8 hr, the Casp3-
TevS-2 cells showed robust GFP-Annexin-V staining (Ernst,
1998), a hallmark of apoptosis involved in the recruitment of
macrophages for engulfment and clearance of apoptotic cells.
By 16 hr, only 25% of the cells remained viable. In contrast, no
increase in DEVDase activity, Annexin-V staining, or cell death
was observed with the Casp3-WT or Casp3-TevS-1 lines treated
with Rap. Similar functional results were obtained for the Casp7-
TevS-2 line, which showed a 6-fold induction of DEVDase
activity by 6 hr, an increase in Annexin-V staining by 8 hr, and
a large decrease in cellular viability by 16 hr (Figure 3A). Overall,
the relative phenotypic consequences of the WT, TevS-1, and
TevS-2 lines were similar for procaspase-3 and procaspase-7,
although total DEVDase activity and Annexin-V staining were
less for activated Casp7-TevS-2 as compared to the corre-
sponding procaspase-3 allele. These data establish that
SNIPer-mediated cleavage and activation of either procas-
pase-3 or -7 at site-2 alone is sufficient to induce robust caspase
activation and rapid apoptosis in human cells.
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Figure 4. Caspase-3 and -7 Regulation by
the Proteasome
(A) The Casp3-TevS-2 line was treated with DMSO
or 10 nM Rap ± 5 mM MG-132 for 6 hr and cell
lysates were blotted with anti-FLAGM2 (left panel,
top) or anti-caspase-3 (left panel, bottom) anti-
bodies. The expected processing intermediates
detected by each antibody are shown to the right
of the immunoblots. The Casp7-TevS-2 line was
treated with 10 nM Rap for 4 or 8 hr ± 500 nM
PS-341 and immunoblotted with anti-FLAG M2
(right panel) and anti-GAPDH.
(B) The Casp3-TevS-2 line was transfected with
pcDNA3.1-V5-Ubiquitin for 24 hr and treated with
DMSO, 10 nM Rap, or 10 nM Rap + 500 nM PS-
341 for 4 hr. Cell lysates were immunoprecipitated
with anti-FLAG M2 agarose and immunoblotted
for covalent ubiquitin with an anti-V5 antibody or
with anti-flag to assess caspase-3 recovery.
(C) The Casp3-TevS-2 and Casp7-TevS-2 lines
were treated with 10 nM Rap (blue bars) or 10 nM
Rap and 5 mM MG-132 (orange bars). Caspase
activity was measured every 1.5 hr in triplicate
(error bars ± SD).
(D) Casp3-TevS-2 and Casp7-TevS-7 cell lines
were treated with 10 nM Rap ± 5 mM MG-132
and assayed for caspase activity as above (top)
or by staining with GFP-Annexin-V and PI and
imaging with fluorescent microscopy (bottom)
for indicated time courses in triplicate (error
bars ± SD).
See also Figure S4.To further understand the functional consequences of prodo-
main cleavage in cells, we compared the D2A-TevS-2 and
TevS-(1,2) alleles (Figure 3B). In parallel to the in vitro results, pro-
domain removal is neither necessary nor sufficient for caspase
activation and apoptosis in cells. A comparison of the lines ex-
pressing TevS-2, D2A-TevS-2, and TevS-(1,2)-Casp7 suggested
that prodomain removal results in modestly lower DEVDase
activity at 6 hr (40%) and reduced Annexin-V staining.
It has been proposed that the executioner caspases may
amplify apoptotic pathways via cleavage of Bid to generate
tBid, which induces mitochondrial outer membrane permeability
(MOMP), cytochrome c release, and activation of caspase-9
(Green, 2005) (Figure S3A). To examine if executioner caspase
activation can ‘‘feedback’’ and result in the activation of initiator
caspases, we tested whether SNIPer-mediated activation of the
Casp-7-TevS-2 allele was sufficient to promote MOMP. We
observed several biochemical hallmarks of MOMP after 4 hr of
Rap induction, including Bid cleavage and cleavage of procas-
pase-9 (Figure S3B). As expected, extensive PARP processing
was also detected. These results further confirm the existence
of positive feedback signaling between the executioner cas-
pases and upstream apoptotic pathways.
Activated Caspase-3 and -7 Are Proteasome Substrates
and Are Stabilized by Proteasome Inhibitors
Processing of engineered procaspase alleles by the SNIPer was
examined in cells by immunoblotting with an anti-FLAG antibody
that detects the C-terminal His/FLAG epitope tag on bothCasp3-TevS-2 and Casp7-TevS-2 constructs. The anti-FLAG
antibodydetects the full-lengthproenzyme (32 kDa), a processed
form cleaved only at site 1 (29 kDa), and the form cleaved at site 2
to generate the small subunit (12 kDa). We also used a polyclonal
caspase-3 antibody that recognizes both caspase-3 subunits.
After the addition of Rap to the Casp3-TevS-2 cell line for 6 hr,
which correlates with the induction of DEVDase activity and
apoptosis, the small subunit (12 kDa) of cleaved caspase-3
could not be readily detected by immunoblot. Similar results
were observed for Casp7-Tevs-2 (Figure 4A).
Recent studies have suggested that caspase-3 is ubiquiti-
nated and degraded by the proteasome (Suzuki et al., 2001;
Choi et al., 2009). To address the role of the ubiquitin-protea-
some system (UPS) in mediating turnover of SNIPer-activated
caspases, we added one of two different proteasome inhibi-
tors, MG-132 or PS-341, in combination with Rap, which stabi-
lized the cleaved caspase subunits for both caspase-3 and
caspase-7, respectively (Figure 4A). Furthermore, Rap and
PS-341 treatment promoted the accumulation of polyubiquiti-
nated caspase-3 detected by immunoblotting as compared to
Rap alone (Figure 4B). To evaluate the effects of proteasome
inhibition on the induction of caspase activity, a time course
of Rap-induced processing of the procaspase-3 and -7 allele
series was performed ± 5 mM MG-132. Addition of MG-132 re-
sulted in a 6- to 8-fold enhancement in Rap-induced DEVDase
activity for those caspase-3 and -7 alleles that were active in
cells (TevS-2, D2A-TevS-2, and TevS-1,2 variants) (Figure 4C;
Figure S4A).Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc. 641
An increase in caspase activity induced by MG-132 directly
correlated to the severity and kinetics of the apoptotic pheno-
type (Figure 4D). For example, at 4 hr, MG-132 increased
Annexin-V staining to 60% of cells compared to 25% with Rap
alone. By 8 hr, almost 50% of the cells were double positive
for Annexin-V and propidium iodide, a marker for the loss of
cell membrane integrity. Thus, selective activation of either cas-
pase-3 or -7 in combination with MG-132 robustly increased the
level of DEVDase activity, accelerated apoptotic hallmarks such
as Annexin-V staining, and, by 8 hr, resulted in a large fraction of
late-stage apoptotic cells. A minor population of cells were PI
positive only, excluding necrotic cell death as the primary
response to proteasome inhibitors. The addition of both Rap
and MG-132 for as long as 8 hr to Casp-3-WT or Casp7-WT
control lines did not induce an increase in caspase activity
(Figure 4C), which further established a direct relationship
between the UPS and the activated forms of capase-3 and -7
generated by the SNIPer. We also tested the possibility that
proteasome inhibitors stabilized the SNIPer itself. However,
HEK293 cells stably expressing both SNIPer and the TevS-
FRET reporter showed no detectable proteasome inhibitor-
dependent enhancement of TEV activity by the FRET assay,
which was further confirmed by immunoblotting to assess
FRET reporter cleavage (Figure S1C).
We observed similar levels of Casp7-TevS-2 activation in
experiments in which MG-132 or the more potent and selective
PS-341 were directly compared (Figure S4B). To determine if
proteasome inhibition promoted executioner caspases in
a second cell line, we coexpressed the SNIPer in HeLa cells
with retroviruses expressing the Casp3-WT and Casp3-TevS-2
alleles, and we successfully activated the SNIPer and Casp3-
TevS-2 in a Rap-dependent fashion (Figure S4C). Moreover,
the level of caspase-3 induction was potently enhanced by
MG-132.
Activation of Caspase-6 Is Not Proapoptotic except
in Conjunction with Proteasome Inhibition
Procaspase-6 activation was tested in vitro and in cells with the
SNIPer. Although procaspase-6 is defined as an executioner
caspase and is closely related to caspase-3 and -7 by sequence
homology, several distinct features have been observed for this
isoform. First, procaspase-6, unlike procaspase-3 and -7, has
been reported to self-activate when overexpressed in 293T cells
(Klaiman et al., 2009). There is an additional loop in the intersubu-
nit linker that bisects a region known as the ‘‘safety catch’’ at the
homologous site in procaspase-3. Second, procaspase-6
prefers Val or Thr at P4 unlike caspase-3 and -7, which prefer
acidic residues at this position (Thornberry et al., 1997). Procas-
pase-6, therefore, resembles the initiator caspases by
a tendency to self-activate and by similar substrate preferences
at P4.
To probe caspase-6 signaling in apoptosis, we applied the
TevS insertion strategy to engineer a series of orthogonal
procaspase-6 alleles. In addition to site 1 at the junction of the
prodomain and the large subunit, there are two reported
cleavage sites in the intersubunit linker of procaspase-6
(Figure 5A): DVVDjN, which we refer to as site 2a, and TEVDjA,
or site 2b. Although TEV protease can process sites with a P10642 Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc.Asn with reduced efficiency, an Ala was substituted at P10 to
enhance proteolysis at site 2a. Thus, three TevS alleles were en-
gineered by insertion at each of the three reported sites (site 1,
site 2a with a P10 Ala, and site 2b).
Each construct was expressed in E. coli and processed
in vitro with recombinant TEV protease or recombinant active
caspase-3, which is capable of activating WT procaspase-6.
A fluorogenic Ac-VEID-AFC peptide substrate, the preferred
substrate for caspase-6, was used in these experiments (Fig-
ure 5B). TEV protease could process and activate the TevS-2
variants (2a and 2b), whereas recombinant caspase-3 activated
Casp6-WT and, unexpectedly, Casp6-TevS-2b. Because this
allele is WT at site 2a, and caspase-3 was not able to activate
the TevS variants at site 2a, we infer that site 2a is a functional
caspase-3 processing site (Figure 5B). TEV protease did activate
Casp6-TevS-2awith anAsn at P10 (data not shown), but total VEI-
Dase activity was less than that of the Ala mutant.
Casp6-TevS variants were transduced into HEK293 cells with
the SNIPer, and cell-based assays were employed to measure
caspase-6 activity in cells. Casp6-TevS-2a was nearly fully pro-
cessed by the SNIPer by 6 hr (Figure S5A), but induced VEIDase
activity was only 2.4-fold above the control (Figure 5C, left
panels). Cellular viability was not significantly affected by cas-
pase-6 activation at 16 or 24 hr post-Rap for the Casp6-TevS-2a
line as compared to Casp6-WT or to an empty vector control
(Figure 5D), and we did not observe a significant apoptotic
response by Annexin-V staining (Figure 5C, right panels).
We hypothesized that the UPS may negatively regulate cas-
pase-6 activity as well. Cells harboring the SNIPer and the
Casp6-TevS-2a allele were treated with Rap ± MG-132.
Remarkably, VEIDase activity with Rap and MG-132 was
elevated 14-fold at 4 hr compared to Rap alone or to
Casp6-WT or Casp6-TevS-1 control lines (Figure 5C, left
panels). Amplification of VEIDase activity was accompanied
by a dramatic increase (50%) in Annexin-V-positive cells
(Figure 5C, right panels). To further probe the mechanism by
which MG-132 promotes caspase-6 activity and apoptosis,
we immunoblotted for caspase-6 before and after SNIPer-
mediated cleavage. Surprisingly, MG-132 stabilized the
unprocessed Casp6-TevS-2a zymogen (Figure S5A, lanes 1
and 2). This result was independent of SNIPer-induced
cleavage and in stark contrast to the mode of caspase-3
and -7 regulation by the proteasome. When Casp6-TevS-2a
cells were treated with Rap ± MG132 (Figure S5A, lanes 3
and 4), the small subunit was also stabilized with MG-132.
Similar results were obtained with PS-341. We next tested if
caspase-6 activation induced MOMP, and after 8 hr of sus-
tained Casp6-TevS-2a activation with Rap only, we observed
no evidence for MOMP. However, addition of PS-341 and Rap
caused a large increase in Bid cleavage, procaspase-9, and
PARP (Figure S5B). These results suggest that both procas-
pase-6 and activated caspase-6 are targets for negative regu-
lation by the UPS, and caspase-6 is only proapoptotic in the
presence of proteasome inhibitors. The severity of the
apoptotic phenotype directly correlates with increased VEI-
Dase activity in cells, stabilization of both the pro- and active
forms (unlike caspase-3 and -7), and recruitment of the
endogenous apoptotic machinery via MOMP.
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Figure 5. Proteasome Inhibition Converts
Procaspase-6 to an Apoptotic Executioner
Caspase Isoform
(A) Sites for which the TevS insertion was applied
for caspase-6.
(B) In vitro caspase activity of the procaspase-6
matrix of orthogonal alleles is presented as
a heat map (top). Caspase activity was measured
by expressing each allele in E. coli, treating with
active caspase-3 (2 nM) or Tev protease (1.1 mM)
for 1 hr with 30 mM Ac-VEID-AFC in triplicate, cor-
recting for caspase-3 VEIDase activity where
appropriate. Abbreviations: WT, wild-type; TevS-
2a, TevS insertion at site 2a with P10 Ala; TevS-
2b, TevS insertion at site 2b. Alignment of the
protein sequences of procaspase-3 (CASP3_HU-
MAN) and procaspase-6 (CASP6_HUMAN) indi-
cates an extra loop region in caspase-6 that
harbors sites 2a and 2b.
(C) The Casp6-WT (top) line was treated with
10 nM Rap ± 5 mM MG-132 over a course of 8 hr
and assayed for caspase-6 activity with 50 mM
VEID-R110 (left) or by staining with GFP-An-
nexin-V imaging with fluorescent microscopy.
Casp6-TevS-2 (bottom) was treated identically.
The inset is the same assay in the range of 0–3
RFUs. Data are presented as the average from
an experiment performed in quadruplicate (error
bars ± SD).
(D) The Casp3-TevS-2 line was treated with 10 nM
Rap for 16 or 24 hr and cell viability was measured
with Cell Titer-Glo (Promega, WI).
See also Figure S5.Caspases Attack the 26S Proteasome, and Caspase
Activation Synergizes with Proteasome Inhibition
Recently gel-based proteomic data from several other labora-
tories have identified 10 proteins from the 26S proteasome,
mostly in the 19S cap, that are cleaved during apoptosis
(Sun et al., 2004; Adrain et al., 2004; Van Damme et al.,
2005; Thiede et al., 2005 Jang et al., 2007). We have
described a proteomics strategy for the global identification
of protease substrates in mammalian cells (Mahrus et al.,
2008). This method utilizes an engineered protein ligase called
subtiligase to biotin-tag and enrich for nascent N termini
produced during proteolysis, which are then sequenced by
liquid chromatography-tandem mass spectrometry (LC-MS/
MS). A distinct advantage to this technology is that the exact
site of proteolysis is identified. Our group has identified >1000
caspase substrates in several cell lines induced by a variety of
apoptotic drug stimuli (S.M., H. Nguyen, and J.A.W., unpub-
lished data). Within this dataset, we found 12 caspase
substrates in the 26S proteasome and defined their cleavage
sites from MS/MS data (Table S1). Ten of these are novel.
Surprisingly, the substrate list included two additional
a subunit sites and three b subunit sites of the 20S catalytic
core particle. One of the three b subunit cleavage sites iden-
tified by our degradomics experiments, PSB7_HUMAN or
b2, is a bona fide proteasome catalytic subunit, providing
trypsin-like hydrolase activity to the complex. The site of cas-
pase proteolysis in the b2 subunit is only 10 residues from the
catalytic N-terminal nucleophile and was likely missed inprevious gel-based studies. These mass spectrometry data
do not address the extent of cutting for each of these subunits
by caspases, nor their functional impact. Nonetheless, the
aggregate of our data plus previous publications show that
20 of 33 of the subunits in the 26S proteasome can be cleaved
in a cellular context by caspases (Figure 6A). Further studies
will be required to assess the functional impact and timing
of these individual cuts on proteasome function.
We then assayed for proteasome function during apoptosis in
our system. As caspase activity increased upon activation of the
Casp3-TevS-2 allele by the SNIPer, proteasome activity
decreased coincidently (Figure 6B). These data lead us to
hypothesize that there is a negative feedback loop between
the executioner caspases and the proteasome (Figure 6C).
This model predicts that caspase activation should synergize
with proteasome inhibition. To test this prediction, wemodulated
the activation of Casp3-TevS-2 by the SNIPer by titrating Rap
(EC50 of 4 nM for SNIPer activation of the caspases) in combi-
nation with titration of MG-132 to achieve a range of proteasome
inhibition (IC50 of 0.8 mM). We observed dramatic synergy
between caspase-3 activation and inhibition of the proteasome
(Figure 6D). For example, at the EC50 for SNIPer activation by
Rap (2 nM), the addition of saturating MG-132 (5 mM) yielded
a 7.7-fold induction of caspase activity as compared to 1.6-
fold induction with Rap only. Similarly, at the EC50 for MG-132
(0.8 mM), addition of saturating amounts of Rap (8 nM) induced
an 8.9-fold increase in caspase activity as compared to 2.8-
fold with Rap alone.Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc. 643
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Figure 6. Reciprocal Negative Regulation
between the 26S Proteasome and Execu-
tioner Caspases
(A) Novel and published proteasome subunits iden-
tified as caspase substrates are mapped to an
inventory of 20S core, 19S lid/base, and 11S acti-
vator subunits (left). Cleaved subunits (red) are
also mapped onto a model of the fully assembled,
multimeric 26S proteasome (right).
(B) The Casp3-TevS-2 line was treated with 10 nM
Rap over a course of 8 hr and assayed for caspase
activity with Caspase-Glo-3/-7 and protease
activity with Proteasome-Glo (Chymotrypsin-Like).
Data are presented as the average from an experi-
ment performed in triplicate (error bars ± SD; note
different scales).
(C) A model for reciprocal negative regulation
between activated executioner caspases and the
26S proteasome-ubiquitin system predicts synergy
between caspase activation and proteasome inhi-
bition.
(D) The Casp3-TevS-2 line was cotreated with the
indicated concentrations of Rap (0–8 nM) and
MG-132 (0–5 mM) for 4 hr and caspase activation
was measured with Caspase-Glo-3/-7 in triplicate.
See also Table S1.DISCUSSION
Design Considerations for SNIPer
We envisioned an inducible orthogonal protease and substrate
system with the following design principles: (1) the orthogonal
protease should have no reported substrates in the human or
mouse proteome, (2) expression and activation must be well
tolerated in mammalian cell lines that stably express the
protease, (3) the time course of induced protease activity should
match or exceed the expected time course of apoptosis, (4) the
cognate protease substrate sequence must be tolerated within
the context of the target protein, and (5) there can be no ‘‘leaky’’
protease activity when the orthogonal protease and an engi-
neered caspase isoform are coexpressed in living cells.
The remarkable specificity of TEV protease is attributed to
the 7-mer cleavage sequence ENLYFQ/S (Parks et al., 1994).
Although TEV is most often used as recombinant protein
in vitro, the Naysmith group demonstrated that TEV protease
is well tolerated when expressed in S. cervisiae or D. mela-
nogaster (Pauli et al., 2008; Uhlmann et al., 2000), and that
ectopic TEV protease expression is capable of cleaving
specific protein targets with genetically encoded TevS
sequences. Wehr and coworkers elegantly expanded upon
this approach by engineering a split-TEV construct based on
protein complementation assay technology, and they demon-
strated regulated TEV protease activity in several diverse
cell-culture systems (Wehr et al., 2006). However, when we im-
plemented this design as fusions to the ligand-binding domains
FKBP and Frb, there was only modest control of activity upon
addition of Rap, especially at higher expression levels, and
Williams and colleagues recently observed a similar phenom-
enon (Williams et al., 2009).
We made two essential changes to the previous split-TEV
construct: (1) removal of the C-terminal peptide from the644 Cell 142, 637–646, August 20, 2010 ª2010 Elsevier Inc.C-domain in order to prevent the spontaneous association
between N- and C-TEV fragments in the absence of Rap and
(2) optimization of the fusion domain partners such that Frb is
fused to N-TEV and FKBP to the truncated C-TEV variant. We
detect little to no background caspase activity for TevS-caspase
alleles in the absence of Rap, and stable cell lines harboring
these alleles and the SNIPer were readily produced and showed
no impairment of growth (data not shown). Both fragments of the
SNIPer exhibited reasonable posttranslational stability in cells,
and Rap-induced activation was rapid and synchronous as
compared to endogenous caspase pathways.
Orthogonal Activation of the Executioner Caspases
Reveals Regulation by the UPS
The SNIPer can be used to synchronize populations of cells ex-
pressing caspase alleles that mimic discrete states of caspase
activation, and this approach has revealed the specific process-
ing requirements for executioner caspase activation andmatura-
tion, which are difficult to deconvolute in cells (Pop andSalvesen,
2009). Targeted and synchronous caspase activation may facili-
tate additional functional studies to understand how cell-to-cell
variability, pathway redundancy, and multiple levels of positive
and negative feedback regulate cell death processes.
The constructs presented here should also serve as important
tools for further studying the role of the UPS in restraining cas-
pase activity. A recent study demonstrated that prodomain
release was necessary for cIAP-1 binding to caspase-7, which
is then polyubiquitinated in vitro upon binding cIAP-1 (Choi
et al., 2009). Our TevS insertion strategy maintains the native
P10 residue, and cIAP-1 binding to cleaved caspase-7 explicitly
depends on the presence of the N-terminal Ala of the large
subunit. We have conducted preliminary studies showing that
RNAi-mediated knockdown of cIAP-1, cIAP-2, or XIAP has
a modest effect (1.5- to 2-fold) on enhancing caspase-3 or -7
activity induced by the SNIPer (data not shown). Nevertheless,
depletion of individual Inhibitor or Apoptosis Proteins (IAPs) did
not phenocopy pharmacological inhibition of the proteasome.
Several factors could explain this result, including redundancy
between the IAPs, different cellular compartment(s) where the
SNIPer is activating caspases as compared to DISC or the apop-
tosome, the stoichiometry of orthogonal caspase to IAP expres-
sion, and the kinetics of the SNIPer relative to endogenous
initiator caspases. Alternatively, additional E3-ligases may
mediate caspase degradation.
Orthogonal caspase activation by the SNIPer revealed
synergy between caspase activation and pharmacological inhi-
bition of the proteasome, and these data are consistent with
a model in which the UPS potently restricts executioner caspase
activity while the caspases disable the proteasome via subunit
proteolysis during apoptosis. Our new proteomics data reveal
that caspase proteolysis of the proteasome subunits is more
extensive than previously reported. Strikingly, caspase-6 can
induce apoptosis only when activated in combination with pro-
teasome inhibitors, and in this context the UPS appears to
control the propagation of positive feedback from SNIPer-
induced caspase activation to MOMP.
This is the first example of reciprocal negative regulation
between proteases that we are aware of. Mutual antagonism
between signaling molecules is metabolically ‘‘expensive,’’ but
it is a common regulatory motif that allows for rapid pulses of
activity (Rosenfeld et al., 2002), and we believe that the protea-
some may also constrain homeostatic (nonapoptotic) caspase
activity in this fashion. Our data also provide an additional mech-
anism for bistability in apoptotic signaling. There are additional
feedback loops between the executioner caspases and their
substrates in apoptosis pathways, including caspase proteolysis
of substrates yielding neo-epitopes that mimic SMAC/Diablo, an
IAP inhibitor (Hell et al., 2003).
The caspase-6 zymogen is essentially converted to an
apoptotic effector caspase by MG-132. Recently, a targeted
knockout of PSMC1 (a 19S proteasome subunit) in the mouse
neuron resulted in the depletion of the 26S proteasome and
yielded a neurodegenerative-like phenotype including the pres-
ence of cleaved caspases (Bedford et al., 2008). Similarly, genet-
ically encoded proteasome reporters are potently induced in the
presence of pathogenic Huntington’s disease (HD) alleles (Wang
et al., 2008). Caspase-6 has already been implicated in the path-
ogenesis of the disease, but in the context of the present data,
a second proteasome-caspase axis of mutual antagonism could
exist in which HD patients could have impaired neuronal UPS
function, stabilizing and potentially activating procaspase-6,
which has been implicated in cleaving Htt (Graham et al.,
2006), a crucial event in the etiology of the disease.
The proteasome inhibitor Bortezemib (PS-341) is approved as
first-line therapy for treating multiple myeloma (MM), a severe
hematopoetic malignancy caused by the clonal proliferation of
plasma cells (Raab et al., 2009). Proteasome inhibitors induce
apoptosis in these cell types (Lee et al., 2003), which can be
blocked by caspase inhibitors. Much research has focused on
Bortezemib’s therapeutic effect on NF-kB signaling, although
recent evidence has also pointed to downregulation of MAPK
signaling, p53 activation, and stabilization of p27, a cell-cycleinhibitor. Our model implies an additional mechanism: stabiliza-
tion of the executioner caspases. As a single agent in MM,
Bortezemib-mediated caspase stabilization may reduce the
apoptotic threshold in these cells. Our data further suggest
that combinations of proapoptotic agents to activate the cas-
pases and proteasome inhibitors may synergize to induce
apoptosis in additional cancer types.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
The 293T (ATCC#CRL-11268) and HEK293 (ATCC#CRL-1573) cell lines were
obtained from the UCSF Cell Culture Facility, and the HeLa (ATCC#CCL-2) cell
line was obtained from ATCC. Cells were passaged in MEM with Earle’s
Balanced Salt Solution supplemented 1with 0% FBS (Invitrogen), 1 mM
Sodium Pyruvate, 2 mM L-Glutamine, 13 Non-Essential Amino Acids, and
100 mg/ml Normocin (Invivogen).
Transient transfection of plasmids was performed at the 12- or 6-well plates
scale. Wells were coated with poly-d-lysine prior to plating target cells. Cells
were plated to reach 90% confluence the following day, and transfection
mixes were prepared according to the standard Lipofectamine 2000 protocol.
For FRET studies, N- and C-TEV fragments were cotransfected over a range of
3:1 to 12:1 molar excess to the TEV-FRET reporter. Rap (Calbiochem) and
MG-132 (Sigma) were dissolved in DMSO and were stored as aliquots at
20C. Please see the Extended Experimental Procedures for the details of
plasmid construction and Table S2 for all DNA oligonucleotide sequences
used in this paper.
Phenotypic Analysis of Caspase Activation in Cells
Caspase-Glo-3/-7, Proteasome-Glo (Chymotrypsin-like activity), and CellTiter-
GloAssays (Promega)wereperformedaccording to themanufacture’sprotocol.
Replicate wells in a 96-well plate were mock-treated or with 10 nM Rap. At
defined endpoints, equal volume of either reagent was added to cells. Cellular
lysis proceeded at room temperature for 30 min, and luciferase activity was re-
corded in theSpectraMaxM5plate readerwith an integration time of 500ms. To
measure caspase-6 activity, a VEID-R110 (rhodamine 110-based caspase-6
substrate) was used. VEID-R110 was added to a final concentration of 50 mM.
To assay for PS exposure and membrane integrity, 1 ml GFP-Annexin-V, a gift
ofDr. Joel Ernst (NewYorkUniversity),and5mg/mlpropidium iodidewereadded
to cells with Annexin-V assay buffer (13 final concentration 10 mM HEPES,
pH 7.4; 140 mM NaCl; and 2.5 mM CaCl2). After 10 min at 37
C, fluorescent
imaging was performed in the Incell Analyzer 1000 (GE Healthcare).
SUPPLEMENTAL DATA
Supplemental Data includes Extended Experimental Procedures, five figures,
Supplemental References, and two tables and can be found with this article
online at doi:10.1016/j.cell.2010.07.014.
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